Integrating Omics Data and AI for Cancer Diagnosis and Prognosis
Cancers · 03.07.2024 · 16 (13) · 2448
DOI: 10.3390/cancers16132448 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 03.07.2024. Verfasst von Yousaku Ozaki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA. Die Arbeit wurde bisher 69-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health, National Institute of General Medical Sciences of the National Institutes of Health, Prisma Health.
Abstract (Originalsprache)
Cancer is one of the leading causes of death, making timely diagnosis and prognosis very important. Utilization of AI (artificial intelligence) enables providers to organize and process patient data in a way that can lead to better overall outcomes. This review paper aims to look at the varying uses of AI for diagnosis and prognosis and clinical utility. PubMed and EBSCO databases were utilized for finding publications from 1 January 2020 to 22 December 2023. Articles were collected using key search terms such as “artificial intelligence” and “machine learning.” Included in the collection were studies of the application of AI in determining cancer diagnosis and prognosis using multi-omics data, radiomics, pathomics, and clinical and laboratory data. The resulting 89 studies were categorized into eight sections based on the type of data utilized and then further subdivided into two subsections focusing on cancer diagnosis and prognosis, respectively. Eight studies integrated more than one form of omics, namely genomics, transcriptomics, epigenomics, and proteomics. Incorporating AI into cancer diagnosis and prognosis alongside omics and clinical data represents a significant advancement. Given the considerable potential of AI in this domain, ongoing prospective studies are essential to enhance algorithm interpretability and to ensure safe clinical integration.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC 29605, USA.
- Department of Computer Science and Engineering, Molinaroli College of Engineering and Computing, Columbia, SC 29208, USA.
- Prisma Health Cancer Institute, Prisma Health, Greenville, SC 29605, USA.
ORCID-Profile: Yousaku Ozaki, Phil Broughton, Hamed Abdollahi, Homayoun Valafar, Anna V Blenda
Förderung
- Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health
- National Institute of General Medical Sciences of the National Institutes of Health
- Prisma Health
Zitieren
APA
Ozaki, Y., Broughton, P., Abdollahi, H., Valafar, H., & Blenda, A. V. (2024). Integrating Omics Data and AI for Cancer Diagnosis and Prognosis. Cancers, 16(13), 2448. https://doi.org/10.3390/cancers16132448
Vancouver
Ozaki Y, Broughton P, Abdollahi H, Valafar H, Blenda AV. Integrating Omics Data and AI for Cancer Diagnosis and Prognosis. Cancers. 2024;16(13):2448. doi:10.3390/cancers16132448
BibTeX
@article{Ozaki2024,
author = {Ozaki, Yousaku and Broughton, Phil and Abdollahi, Hamed and Valafar, Homayoun and Blenda, Anna V},
title = {Integrating Omics Data and AI for Cancer Diagnosis and Prognosis},
journal = {Cancers},
year = {2024},
volume = {16},
number = {13},
pages = {2448},
doi = {10.3390/cancers16132448}
}
EUVIMED